<![CDATA[Background:Chronic Kidney Disease (CKD) in children poses a significant global health challenge, often progressing silently until advanced stages. Early detection is critical to initiate timely interventions that can prevent irreversible renal damage, reduce morbidity, and improve long-term outcomes. Despite advances in diagnostics, the effectiveness and implementation of pediatric CKD early detection programs vary globally. Objective:This systematic review aimed to evaluate the effectiveness of early detection programs for CKD in children, focusing on their impact on early diagnosis, disease progression, and clinical outcomes across different healthcare settings. Methods:Following PRISMA 2020 guidelines, a comprehensive search was conducted in PubMed, Scopus, Web of Science, Embase, and Cochrane Library from January 2015 to September 2025. Eligible studies included randomized controlled trials, cohort, cross-sectional, and case-control studies evaluating early detection or screening programs for pediatric CKD. Data were extracted on study design, screening type, outcomes, and implementation characteristics. Quality assessment was performed using Cochrane RoB 2.0, Newcastle–Ottawa Scale, and JBI tools. Results:Out of 2,161 identified records, 28 studies met inclusion criteria. Most studies originated from Asia (Japan, Korea, India, Iran) and Europe. School-based urinary screening and risk-targeted screening programs demonstrated effectiveness in detecting asymptomatic CKD at earlier stages and facilitating timely nephrology referrals. Biomarker-based approaches—such as cystatin C, netrin-1, NGAL, and KIM-1—significantly improved diagnostic accuracy compared to serum creatinine alone. Integrating biomarker screening with school and primary-care programs improved early detection rates and reduced CKD progression risk. However, cost-effectiveness and sustainability remain major challenges, especially in low- and middle-income countries. Conclusion:Early detection programs for pediatric CKD are effective in identifying renal impairment at subclinical stages, enabling early intervention and slowing disease progression. The combination of population-based screening and biomarker-guided testing offers the best balance between sensitivity and practicality. Future research should prioritize standardizing screening protocols, integrating digital tools and AI-based risk prediction, and evaluating long-term cost-effectiveness to inform global pediatric nephrology policies.]]>
